EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effect of SSRIs on clinical progression in amnestic mild cognitive impairment stratified by Alzheimer's disease pathology

Yan Li, Wenying Liu, Xuechu Wang, Wei Qin, Zhaojun Liu, Diyang Lyu, Ying Li, Bingqiu Li, Lingzhi Xu, Shuman Cao, Alzheimer's Disease Neuroimaging Initiative, Joyce R F Chong und 3 weitere

Alzheimer's & Dementia · 2025

DOI: 10.1002/alz.70946 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Yan Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical Uni…. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Selective Serotonin Reuptake Inhibitors, Alzheimer Disease, Amnesia. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Postdoctoral Fellowship Program (Grade C) of China Postdoctoral Science Foundation, Key Project of the Science and Technology Innovation Elite Program, National Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION This study examined whether selective serotonin reuptake inhibitors (SSRIs) treatment influenced cognitive trajectory and progression to Alzheimer's disease (AD) dementia in amnestic mild cognitive impairment (MCI) patients, stratified by AD pathology. METHODS Four hundred fifty‐seven amnestic MCI participants in the ADNI database were analyzed. AD pathology was determined by baseline amyloid beta (Aβ) and tau positron emission tomography. Kaplan‐Meier survival analysis and Cox proportional hazards models evaluated MCI‐to‐AD progression. Linear mixed models analyzed longitudinal cognitive trajectories, amyloid accumulation, and cortical thickness. RESULTS SSRI treatment showed no significant effect on AD dementia progression (hazard ratio = 1.64, 95% confidence interval: 0.61 to 4.38) or cognitive trajectories, regardless of AD pathology. No significant differences in Aβ accumulation or cortical thickness were observed between SSRI users and non‐users. External validation confirmed no significant SSRI effect on AD progression or cognitive decline. DISCUSSION SSRI treatment was not associated with long‐term cognitive effects in amnestic MCI, irrespective of underlying AD pathology. Highlights SSRI treatment was not associated with long‐term AD dementia risk in MCI. SSRI treatment had no impact on long‐term cognitive performance changes in MCI. SSRI treatment did not affect Aβ accumulation or cortical thickness in MCI. SSRIs had no effect on MCI progression, regardless of underlying AD pathology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cognitive DysfunctionSelective Serotonin Reuptake InhibitorsAlzheimer DiseaseAmnesiaHumansMaleFemaleDisease ProgressionAgedPositron-Emission TomographyAmyloid beta-PeptidesAged, 80 and overtau ProteinsLongitudinal Studies

Stichwörter der Autor:innen

Alzheimer's diseaseamyloid betamild cognitive impairmentselective serotonin reuptake inhibitors

Substanzen

Selective Serotonin Reuptake InhibitorsAmyloid beta-Peptidestau Proteins

Autor:innen und Institutionen

  • The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.
  • Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, P.R. China.
  • Beijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, P.R. China.
  • Clinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing, P.R. China.
  • Center of Alzheimer's Disease, Beijing Institute of Brain Disorders, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing, P.R. China.
  • Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, P.R. China.

ORCID-Profile: Jianping Jia

Förderung

  • Postdoctoral Fellowship Program (Grade C) of China Postdoctoral Science Foundation
  • Key Project of the Science and Technology Innovation Elite Program
  • National Medical Research Council
  • NIA NIH HHS
  • China Postdoctoral Science Foundation
  • Key Project of the National Natural Science Foundation of China
  • National Key Scientific Instrument and Equipment Development Project
  • STI2030-Major Projects

Zitieren

APA

Li, Y., Liu, W., Wang, X., Qin, W., Liu, Z., Lyu, D., Li, Y., Li, B., Xu, L., Cao, S., Alzheimer's Disease Neuroimaging Initiative, Chong, J. R. F., Lai, M. K. P., Chen, C. L. H., & Jia, J. (2025). Effect of SSRIs on clinical progression in amnestic mild cognitive impairment stratified by Alzheimer's disease pathology. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70946

Vancouver

Li Y, Liu W, Wang X, Qin W, Liu Z, Lyu D, et al. Effect of SSRIs on clinical progression in amnestic mild cognitive impairment stratified by Alzheimer's disease pathology. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70946

BibTeX
@article{Li2025,
  author = {Li, Yan and Liu, Wenying and Wang, Xuechu and Qin, Wei and Liu, Zhaojun and Lyu, Diyang and Li, Ying and Li, Bingqiu and Xu, Lingzhi and Cao, Shuman and Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative and Chong, Joyce R F and Lai, Mitchell K P and Chen, Christopher L H and Jia, Jianping},
  title = {Effect of SSRIs on clinical progression in amnestic mild cognitive impairment stratified by Alzheimer's disease pathology},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  doi = {10.1002/alz.70946}
}
Kostenlos starten →